Robotic Sleeve Gastrectomy for Morbid Obesity Our initial experience

Elisabetta Morini MD2, Lea Lucchese MD1, Giusy Pintabona MD1, Viviane DiDio MD1, Antonio Galeano MD1, Antonio Calopresti MD1, Francesco Corallo MD3, Antonino Todaro MD3, Francesco Iaropoli MD1, Antonino Prof. De Lorenzo MD4, Vittorio Lombardo MD FACS1

1. Division of General Surgery, IRCCS Ospedale Piemonte-Messina Italy.
2. Division of Endocrinology, IRCCS Ospedale Piemonte-Messina Italy
3. Division of Neuroscienze, IRCCS Ospedale Piemonte-Messina Italy
4. Department of Biomedicine and Prevention, School of Medicine and Surgery, ""Tor Vergata"" University- Rome, Italy

- 30/04/2022

Abstract

AIM OF THE STUDY: We evaluated the initial result and the very short-term outcomes of Robotic Sleeve Gastretomy at our Institution.

METHODS: A retrospective analysis of the initial 10 patients who underwent Robotic Sleeve Gastrectomy (RSG), between September 2019 and March 2020, was performed. The aim of this study was to assess the safety, the operative time and short-term efficacy of RSG as a treatment option for weight reduction. Data collected included operative time, perioperative complications, length of hospital stay.

RESULTS: Our initial 10 morbidly obese patients, who underwent RSG had an average preoperative BMI 44.6 kg/m2. There were 8 women and 2 men, with mean age 48.6 (range 30 to 61 years). Mean operative time was 1.5 hour (range 1.0-2.0). We had no conversion to open or laparoscopic procedure. There were neither postoperative complications nor mortality. Median hospital stay was 4 days.

CONCLUSIONS: In our initial experience, RSG is a safe and effective treatment option for obese patient. Followup will be necessary to evaluate long-term results.

Keywords: Robotic Bariatric Surgery, Ghrelin, Glucagon-like peptide 1, Morbid obesity, Peptide YY, Sleeve gastrectomy, Surgery, Weight loss.